Interferon alfa-2a and alfa-2b
Pegylated Interferon alfa-2a and alfa-2b, approved for the treatment of
Hepatitis B virus (HBV) and Human Coronavirus (HCV), may be used to
induce innate antiviral responses in patients infected with 2019-nCoV,
and studies involving interferons, such as an approved anti-HCV
combination of pegylated interferon plus Ribavirin, have been initiated
(ChiCTR2000029387). Whether a pegylated interferon and a nucleoside
compound could work synergistically against 2019-nCoV however is
unclear. Their assessment should be closely monitored and dose reduction
or discontinuation of therapy may be needed due to several adverse
effects associated with subcutaneous interferon therapies [37].